| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
KORU Medical Systems, Inc.$4.28
-0.15 (-3.39%)
F 16Pipeline Score MedTech · Clinical
Market Cap
188.33 M
EPS
-0.05
P/E Ratio
-
Value Trade
421.18 K
SEC Financials
Q1 2026Dilution Risk
Revenue
11.76 M
R&D Expenses
1.32 M
Operating CF
14.66 K
Total Assets
28.59 M
Total Liabilities
11.67 M
Equity
16.92 M
D/E Ratio
12,345
4.59 %
Week
1.74 %
1 Month
-11.64 %
3 Month
-5.96 %
6 Month
-1.44 %
5 Year
404.62 %
All Time
Cash Data
Cash Position
8.77 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
104.71 K
52 Week Range
2.68 - 6.61
% held by Insiders
6.56 %
% held by Institutions
56.42 %
Enterprise Value
182.92 M
Total Shares
46.50 M
Short %
1.79 %
Float Shares
37.94 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F16
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 13%
Micro Cap (rank 794 of 911)
Percentile RankKORU Medical Systems, Inc. has significant pipeline risk (16/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KRMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KRMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KRMDKORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress
KORU Medical Systems presented real-world data on the FreedomEDGE Syringe Infusion System at the 51st Annual Oncology Nursing Society Congress. The presentation focused on the system's benefits in infusion clinics. However, specific details about the data or outcomes were not provided in the article.
Read more →KRMDKORU Medical Systems Announces First Quarter 2026 Results
KORU Medical Systems has announced its financial results for the first quarter of 2026. The report includes key metrics and insights into the company's performance during this period. However, specific details regarding revenue, expenses, or other financial indicators were not provided in the article.
Read more →KRMDKORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026
KORU Medical Systems, Inc. will report its first quarter 2026 financial results on May 6, 2026. A conference call and webcast will be held at 4:30 p.m. ET to discuss these results and provide a corporate update. The company specializes in large volume subcutaneous infusion solutions aimed at improving patient quality of life.
Read more →KRMDKORU Medical Systems Announces CEO Transition
KORU Medical Systems announced the retirement of CEO Linda Tharby, effective June 30, 2026, after five years of leadership. Adam Kalbermatten, currently Chief Commercial Officer, will succeed her as CEO on July 1, 2026. The transition reflects the Board's confidence in Kalbermatten's capabilities and the company's strategic direction. Tharby will remain on the Board to support the transition.
Read more →KRMDKORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance
KORU Medical Systems reported a 23.3% increase in Q4 2025 revenues, reaching $10.9 million, driven by strong demand for immunoglobulin therapy. The company also achieved a positive adjusted EBITDA of $0.5 million. For the full year, total revenues rose by 22.2% to $41.1 million, with significant international growth. KORU Medical has initiated guidance for 2026, reflecting optimism about future performance.
Read more →KRMDKORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility
KORU Medical Systems has announced that its Freedom60 Infusion Pump has received EU MDR certification, allowing for commercialization in the European Union. This certification includes compatibility with 50 mL prefilled syringes, enhancing the delivery of subcutaneous immunoglobulin therapy. The FreedomEDGE Infusion System also supports 20 mL prefilled syringes, providing flexibility for patients and clinicians.
Read more →KRMDKORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
KORU Medical Systems, Inc. will report its fourth quarter and full year 2025 financial results on March 12, 2026. A conference call and webcast will follow at 4:30 p.m. ET for management to discuss the results and provide a corporate update. The company specializes in large volume subcutaneous infusion solutions.
Read more →KRMDKORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System
KORU Medical Systems has received FDA 510(k) clearance for its FreedomEDGE® infusion system to deliver RYSTIGGO® (rozanolixizumab-noli). This approval allows healthcare professionals to administer the therapy, enhancing access for patients with generalized myasthenia gravis. The clearance marks a significant expansion of KORU's infusion system capabilities, further establishing its position in the large-volume subcutaneous infusion market.
Read more →KRMDKORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow MAHWAH, NJ
KORU Medical Systems reported preliminary unaudited results for Q4 and the full year 2025, highlighting a significant increase in revenue. The company expects Q4 net revenues to be $10.9 million, a 23% increase year-over-year, and full year revenues of $41.1 million, growing by 22%. Positive operating cash flow has been achieved, with an ending cash balance of $8.9 million. KORU's CEO noted the strong performance and momentum heading into 2026, fueled by the company's strategic expansion and product advancements.
Read more →KRMDKORU MEDICAL SYSTEMS ANNOUNCES 27% Q3 REVENUE GROWTH AND RAISES 2025
Koru Medical Systems reported a substantial revenue growth of 27% for Q3 2025, reaching $10.4 million. The core business segment experienced a 30% increase, propelled by new collaborations in pharmaceutical services and clinical trials. Despite the positive financial growth, the company still faced a net loss of $0.8 million and a decline in domestic core revenues. Additionally, the gross margin has decreased due to rising costs and tariffs, although the company remains optimistic about revenue growth and cash flow improvements for the full year.
Read more →KRMDKORU MEDICAL SYSTEMS ANNOUNCES Q2 2025 FINANCIAL RESULTS, INCLUDING RECORD DOUBLE-DIGIT REVENUE, AND RAISES 2025
Koru Medical Systems reported a strong financial performance for Q2 2025, achieving a 21% year-over-year increase in net revenues, totaling $10.2 million. The company also raised its revenue guidance for the full year 2025, anticipating revenues between $39.5 and $40.5 million. Despite a slight decrease in gross margin, Koru Medical celebrated the milestone of surpassing $10 million in revenue for the first time and continues to enhance its offerings with new managerial hires and FDA submissions for its infusion systems. The firm plans to discuss these results in an upcoming conference call.
Read more →KRMDKORU MEDICAL SYSTEMS ANNOUNCES RECORD Q1 2025 FINANCIAL RESULTS AND RAISES 2025
Koru Medical Systems announced a strong performance in Q1 2025, with net revenues reaching $9.6 million, an increase of 18% from the previous year. The company raised its full-year revenue guidance to between $38.5 million and $39.5 million based on robust growth in its core business. However, despite these positive results, the company noted a significant drop in revenue from pharma services and clinical trials and continued to operate at a loss, albeit decreasing from prior periods. Koru Medical also plans to submit two drug applications for FDA clearance in 2025.
Read more →KRMD▲ +5.5%on this news
KORU Medical Systems Announces Fourth Quarter and Full Year 2024 Financial Results with Record Revenues and Gross Profit; Issues Full Year 2025 Guidance MAHWAH, NJ
KORU Medical Systems reported impressive financial results for the fourth quarter and full year of 2024, highlighting record revenues and gross profits. The company experienced substantial growth in both its core and novel therapies segments, with a notable 122% increase in novel therapies revenue for Q4. Additionally, KORU Medical announced positive cash flow for Q4 and a significant reduction in full-year cash burn. Looking ahead, the company issued optimistic guidance for 2025, expecting revenues to increase by 13% to 16%. The novel therapies segment will be rebranded to better reflect its revenue model.
Read more →KRMDKORU Medical Systems Reports Preliminary Fourth Quarter and Full Year 2024 Results; Achieves Record Full Year and Quarterly Revenues; Positive Cash Flow for the Fourth Quarter MAHWAH, NJ
KORU Medical Systems has reported preliminary fourth quarter and full year 2024 results, showcasing impressive financial growth. The company anticipates fourth quarter net revenues of $8.9 million, a 23% increase from the previous year, and full year revenues of $33.7 million, up 18%. Notably, KORU also achieved a positive cash flow of $0.8 million for the fourth quarter and improved its cash burn by 67% over the prior year. KORU plans to release detailed financial results in March 2025, with expectations of further growth as it expands its market share and product offerings.
Read more →KRMD▲ +7.7%on this news
KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2024 Q3 FINANCIAL RESULTS, THIRD CONSECUTIVE QUARTER OF DOUBLE-DIGIT GROWTH; RAISES FULL YEAR 2024
Koru Medical Systems, Inc. (KRMD) reported its financial results for Q3 2024, highlighting a 17% increase in net revenues to $8.2 million and notable growth in novel therapies, which surged by 276%. This marks the company's third consecutive quarter of double-digit growth. In addition, Koru has raised its full-year revenue guidance to between $32.75 million and $33.25 million, alongside improved gross margin projections. While the company is expanding its patient base and maintaining a healthy cash position, it still recorded a net loss of $1.6 million.
Read more →KRMDKORU MEDICAL SYSTEMS, INC. ANNOUNCES 2024 Q2 FINANCIAL RESULTS, A RECORD QUARTER WITH 22% REVENUE GROWTH; RAISES FULL YEAR 2024
Koru Medical Systems, Inc. reported a strong second quarter for 2024, achieving net revenues of $8.4 million, marking a 22% increase from the previous year. The company raised its revenue and gross margin guidance for the full year, reflecting confidence in its continued growth. Key drivers included significant gains in both the domestic and international markets, as well as advancements in their novel therapies pipeline. Overall, the company demonstrated improved financial performance and operational efficiencies.
Read more →KRMDKORU MEDICAL SYSTEMS, INC. ANNOUNCES 2024 FIRST QUARTER FINANCIAL RESULTS DELIVERING DOUBLE-DIGIT
Koru Medical Systems reported first quarter 2024 financial results, showing an 11% increase in net revenues compared to the previous year, reaching $8.2 million. The company's core business experienced a 14% growth, supported by market expansion and increased prefill adoption rates. While the company is optimistic about its new oncology collaborations, it also faced a 21.3% decline in Novel Therapies revenue. The financial outlook remains positive with a reaffirmed revenue guidance of $31.2 million to $32.2 million for 2024.
Read more →KRMDKORU Medical Systems Announces Successful Appeal in EU Notified Body Review MAHWAH, NJ
KORU Medical Systems announced a successful appeal of a previous audit assessment by The British Standards Institute (BSI), which had recommended against continued certification. As a result, the company is able to proceed without any suspension of sales for its products in the EU. KORU Medical's President and CEO, Linda Tharby, expressed satisfaction with the outcome and emphasized the importance of this decision for the company's growth in international markets.
Read more →KRMDKORU MEDICAL SYSTEMS, INC. ANNOUNCES 2023 FOURTH QUARTER, FULL YEAR FINANCIAL RESULTS, AND 2024
Koru Medical Systems, Inc. reported their financial results for the fourth quarter and full year ending December 31, 2023. The company reported a slight decrease in fourth quarter revenues but an increase for the full year, along with significant growth in their core business. Despite a notable net loss for the quarter, the company highlighted positive cash flow and an improved gross margin. Looking forward, Koru provided revenue guidance for 2024, indicating expectations for substantial growth driven by new product launches and geography expansion.
Read more →KRMD▼ -5.2%on this news
KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2023 THIRD QUARTER FINANCIAL RESULTS and updates full year 2023 outlook MAHWAH, NJ
KORU Medical Systems, Inc. reported its third quarter financial results, showing a net revenue decline of 10% year-over-year, totaling $7.0 million. The decrease was primarily driven by significant drops in the Novel Therapies revenue, which fell by 78.7%. The company has revised its full year revenue guidance down to between $28.0 and $28.5 million, reflecting slower anticipated growth in the U.S. subcutaneous immunoglobulin market. On a positive note, gross margins have improved to 62.0%, and the company has initiated multiple strategic collaborations, bringing the total to 15.
Read more →KRMDKORU MEDICAL SYSTEMS
Koru Medical Systems, Inc. announced the appointment of Edward Wholihan to its Board of Directors on September 28, 2023. Wholihan brings over 25 years of experience in the healthcare sector, most recently as CFO for different life sciences businesses. His strategic insights are expected to significantly contribute to the company's growth and its position in the subcutaneous infusion market. Koru Medical continues to innovate with its FREEDOM Infusion System aimed at improving patient quality of life.
Read more →KRMDKORU MEDICAL SYSTEMS, INC. ANNOUNCES 2023 SECOND QUARTER FINANCIAL RESULTS AND UPDATES FULL YEAR 2023
Koru Medical Systems, Inc. reported a 6% increase in second quarter net revenue, reaching $6.9 million, driven by growth in both domestic and international markets. The company announced a new collaboration for a Phase III study and is focused on innovation in specialty infusion solutions. However, it has revised its full year revenue guidance downwards, now predicting growth of only 11-17% for 2023, citing a contraction in the U.S. subcutaneous immunoglobulin market. Additionally, the company reported a net loss of $2.5 million for the quarter, with increased operating expenses primarily due to research and development efforts.
Read more →KRMDKORU MEDICAL SYSTEMS, INC. ANNOUNCES PRELIMINARY SECOND QUARTER 2023 REVENUES AND PROVIDES BUSINESS
KORU Medical Systems, Inc. reported preliminary second quarter revenues of approximately $6.9 million, reflecting a 6% year-over-year growth. While domestic core revenues increased by 8% and international revenues surged by 17%, Novel Therapies experienced a significant decline of 28%. The company has adjusted its 2023 revenue guidance due to unfavorable conditions in the U.S. subcutaneous immunoglobulin market and shifting timelines for Novel Therapies revenues. Furthermore, KORU Medical appointed Tom Adams as the new Chief Financial Officer.
Read more →KRMDKORU MEDICAL SYSTEMS, INC. ANNOUNCES 2023 FIRST QUARTER FINANCIAL RESULTS strong start to 2023 with 18% revenue growth MAHWAH, NJ
Koru Medical Systems, Inc. reported its first quarter financial results for 2023, showcasing strong performance with an 18% increase in net revenue to $7.4 million. The company experienced double-digit growth across all its business segments, including a 62% jump in its Novel Therapies division. The firm reaffirmed its financial outlook for the full year, expecting revenues between $32.5 and $33.5 million. This growth reflects Koru's strategic efforts and expanding market presence, particularly in home subcutaneous drug delivery systems.
Read more →KRMDKORU Medical Systems Announces 2022 Q4 AND full year Financial Results, Accelerating to 19% REVENUE GROWTH in 2022 MAHWAH, NJ
KORU Medical Systems released its financial results for Q4 and the full year 2022, highlighting a 19% year-over-year revenue growth totaling $27.9 million. The company reported a notable increase in its Novel Therapies revenue, which surged by 329.8%. Despite these positive metrics, KORU Medical also noted an increased net loss for the year, which rose to $8.6 million. Additionally, the company faces challenges with declining gross profit margins resulting from rising manufacturing costs and transitional expenses as it shifts to new facilities.
Read more →KRMDKORU Medical Systems Announces 2022 Third Quarter Financial Results MAHWAH, NJ
Medical Systems Announces 2022 Third Quarter Financial Results NJ - November 9, 2022 -KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovativ
Read more →KRMDKORU Medical Systems Announces 2022 Second Quarter Financial Results MAHWAH, NJ
Medical Systems Announces 2022 Second Quarter Financial Results - August 3, 2022 -KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and
Read more →KRMD▲ +6.9%on this news
KORU Medical Systems Announces 2022 First Quarter Financial Results CHESTER, NY
Medical Systems Announces 2022 First Quarter Financial Results CHESTER, NY - May 4, 2022 - Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and com
Read more →KRMDKORU MEDICAL SYSTEMS ANNOUNCES 2021 Q4
KORU MEDICAL SYSTEMS ANNOUNCES 2021 Q4 AND FULL YEAR FINANCIAL RESULTS - March 2, 2022 - Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and comme
Read more →KRMDKORU Medical Systems to Unveil Updated Strategic Plan at Investor Day
KORU Medical Systems to Unveil Updated Strategic Plan at Investor Day December 01, 2021 04:01 PM Eastern Standard Time CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technolo
Read more →KRMDKORU MEDICAL SYSTEMS ANNOUNCES 2021
KORU MEDICAL SYSTEMS ANNOUNCES 2021 THIRD QUARTER FINANCIAL RESULTS - November 10, 2021 - Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and comme
Read more →KRMDKORU Medical Systems Announces 2021 Second Quarter Financial Results CHESTER, NY
KORU Medical Systems Announces 2021 Second Quarter Financial Results CHESTER, NY - August 11, 2021 - Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturin
Read more →KRMDKORU Medical Systems Reports Fourth Quarter and Full Year 2020 Financial Results CHESTER, NY
KORU Medical Systems Reports Fourth Quarter and Full Year 2020 CHESTER, NY - March 23, 2021 - Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company") a leading medical technology company focused on the development, manufacturing, and c
Read more →KRMDKORU Medical Systems Announces New Chief Executive Officer CHESTER, NY
KORU Medical Systems Announces New Chief Executive Officer CHESTER, NY - March 19, 2021 - Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and comm
Read more →KRMDKORU Medical Systems Reports Preliminary Full Year 2020 Results; Announces CEO Transition CHESTER, NY
KORU Medical Systems Reports Preliminary Full Year 2020 Results; Announces CEO Transition CHESTER, NY - January 25, 2021 - Repro Med Systems, Inc. dba KORU Medical Systems NASDAQ: KRMD) ("KORU Medical" or the "Company") a leading medical technology company focused on the develo
Read more →KRMDKORU MEDICAL SYSTEMS ANNOUNCES FINANCIAL RESULTS FOR THIRD QUARTER 2020 CHESTER, NY
KORU MEDICAL SYSTEMS ANNOUNCES FINANCIAL RESULTS FOR THIRD QUARTER 2020 CHESTER, NY - November 3, 2020 - Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company") today announced financial results for the third quarter ended September 30,
Read more →KRMDKORU MEDICAL SYSTEMS ANNOUNCES 2020 SECOND QUARTER FINANCIAL RESULTS Record Net Sales of $7.7 Million, Gross Margin of 64% CHESTER, NY
KORU MEDICAL SYSTEMS ANNOUNCES 2020 SECOND QUARTER FINANCIAL RESULTS Record Net Sales of $7.7 Million, Gross Margin of 64% CHESTER, NY - August 4, 2020 - Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company") today announced financial
Read more →KRMDKORU Medical Commences Public Offering of Common Stock CHESTER, NY
KORU Medical Commences Public Offering of Common Stock CHESTER, NY, June 18, 2020 BUSINESS WIRE -- Repro Med Systems, Inc. d/b/a KORU Medical Systems (Nasdaq: KRMD) ( KORU Medical ) today announced that it has commenced an underwritten public offering of the sale of its shares o
Read more →KRMDKORU MEDICAL SYSTEMS ANNOUNCES 2020 FIRST QUARTER FINANCIAL RESULTS Q1 2020 Summary Net sales rose 27% to $6.3 million Gross margin of 60% (62% excluding inventory obsolescence charge) Net income improved to $0.4 million
KORU MEDICAL SYSTEMS ANNOUNCES 2020 FIRST QUARTER FINANCIAL RESULTS - Net sales rose 27% to $6.3 million - Gross margin of 60% (62% excluding inventory obsolescence charge) - Net income improved to $0.4 million, or $0.01 per share - Adjusted EBITDA increased 38% to $1.3 million
Read more →KRMDKORU Medical Systems Announces Record 2019 Fourth Quarter and Full Year Financial Results Conference Call Scheduled for February 26 at 9:00 am ET Q4 2019 Highlights Net sales rose 45.7% to $6.2 million Gross margin of 63
KORU Medical Systems Announces Record 2019 Fourth Quarter and Full Year Financial Results Conference Call Scheduled for February 26 at 9:00 am ET - Net sales rose 45.7% to $6.2 million - Gross margin of 63.4% - Net loss narrowed to $0.1 million - Adjusted EBITDA increased 47.3
Read more →KRMDKORU Medical Systems Announces Record 2019 Third Quarter Financial Results Conference Call Scheduled for November 6 at 9:00 am ET Q3 2019 Highlights Net sales rose 45.5% to a record $6.6 million Gro
KORU Medical Systems Announces Record 2019 Third Quarter Financial Results Conference Call Scheduled for November 6 at 9:00 am ET - Net sales rose 45.5% to a record $6.6 million - Gross margin improved to 66.2% - Operating profit increased 70.8% to $0.8 million - Net income
Read more →KRMDRMS MEDICAL PRODUCTS ANNOUNCES REBRANDING TO KORU MEDICAL SYSTEMS NEW TICKER SYMBOL "KRMD" CHESTER, NY
RMS MEDICAL PRODUCTS ANNOUNCES REBRANDING TO KORU MEDICAL SYSTEMS NEW TICKER SYMBOL "KRMD" CHESTER, NY - October 23, 2019 - Repro Med Systems, Inc. (NASDAQ: REPR) ("the Company") today announced a new dba name, KORU Medical Systems, which the Company will begin using in place
Read more →KRMDRMS MEDICAL PRODUCTS APPOINTS HEALTHCARE INDUSTRY VETERAN R. JOHN FLETCHER TO BOARD OF DIRECTORS Former Chairman of Spectranetics Corporation; NACD 2018 Director of the Year CHESTER, NY
RMS MEDICAL PRODUCTS APPOINTS HEALTHCARE R. JOHN FLETCHER TO BOARD OF DIRECTORS Former Chairman of Spectranetics Corporation; NACD 2018 Director of the Year CHESTER, NY - May 8, 2019 - Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) ("RMS Medical") today annou
Read more →KRMDRMS Medical Products Announces 2019 First Quarter Financial Results Record Quarterly Net Sales of $5.0 Million, Up 23% From Prior Year Conference Call Scheduled for May 1 at 9:00 am ET Q1 2019 Overview Net sales rose 23.
RMS Medical Products Announces 2019 First Quarter Financial Results Record Quarterly Net Sales of $5.0 Million, Up 23% From Prior Year Conference Call Scheduled for May 1 at 9:00 am ET - Net sales rose 23.3% from prior year to $5.0 million - a quarterly record - Gross margin o
Read more →KRMDRMS Medical Products Announces Record Revenue and Profitability for 2018; Outlines Plan for Continued Strong Growth Reported record 2018 revenue of $17.4 million, up 12.4% compared to 2017 Improved 2018 Profitability; im
RMS Medical Products Announces Record Revenue and Profitability for 2018; Outlines Plan for Continued Strong Growth - Reported record 2018 revenue of $17.4 million, up 12.4% compared to 2017 - Improved 2018 Profitability; improved Gross Margin, record Net Income and Adjusted EBI
Read more →KRMDRMS Medical Announces New CEO, Strategic Plan, and Upcoming Schedule Don Pettigrew promoted to President and Chief Executive Officer Reconstituted Board of Directors approves management's strategic growth initiative to b
RMS Medical Announces New CEO, Strategic Plan, and Upcoming Schedule - Don Pettigrew promoted to President and Chief Executive Officer - Reconstituted Board of Directors approves management's strategic growth initiative to become the leading subcutaneous drug delivery partner
Read more →KRMDRMS Medical Products Announces Private Placement Transaction Between Shareholders Chester, NY /
RMS Medical Products Announces Private Placement Transaction Between Shareholders Chester, NY / December 17, 2018 / Repro Med Systems, Inc. dba RMS Medical Products ("RMS" or the "Company") (OTCQX: REPR) today announced that certain of its stockholders (the "Selling Stockholder
Read more →KRMDRMS Medical Products Announces New Board Members Chester, NY /
RMS Medical Products Announces New Board Members Chester, NY / December 6, 2018 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced the addition of two new independent members to the Board of Directors and changes to its bylaws. Effective December
Read more →KRMDRMS Medical Products Third Quarter 2018 Results Conference Call October-24-2018 Confirmation #13684282 Page 1 RMS Medical Products Third Quarter 2018 Results Conference Call October-24-2018 Confirmation #13684282 Operato
RMS Medical Products Third Quarter 2018 Results Conference Call Confirmation #13684282 RMS Medical Products Third Quarter 2018 Results Conference Call Confirmation #13684282 Operator: Greetings and welcome to the RMS Medical Products third quarter 2018 results conference cal
Read more →KRMDRMS Medical Products Announces Second Straight Record Quarterly Net Sales and Net Income Net Sales for the quarter ended
RMS Medical Products Announces Second Straight Record Quarterly Net Sales and Net Income - Net Sales for the quarter ended September 30, 2018 increased 18.1% over the same period last year - Gross Profit increased 21.6% over third quarter 2017 to $2.9 million, or 63.6% of Net Sa
Read more →KRMDRMS Medical Products Announces Record Quarterly Sales and Net Income Net Sales for the quarter ended
RMS Medical Products Announces Record Quarterly Sales and Net Income - Net Sales for the quarter ended June 30, 2018 increased 17.6% over the same period last year - Net Income increased to $475,723 or 10.6% of Net Sales - Inaugural conference call August 7 th at 9:00 AM ET CHE
Read more →KRMDRMS Medical Pre-Announces Strong Quarterly Sales Growth and Change in Leadership Quarterly Net Sales increased 17.6% over the comparable period. Fifth consecutive quarter of Net Sales growth. Announced appointment of Dan
RMS Medical Pre-Announces Strong Quarterly Sales Growth and Change in Leadership - Quarterly Net Sales increased 17.6% over the comparable period. - Fifth consecutive quarter of Net Sales growth. - Announced appointment of Dan Goldberger as Chairman and interim Chief Executive O
Read more →KRMDRMS Medical Products Victory as U.S. Federal Circuit Court of Appeals Invalidates EMED Technologies Corp.'s Patent, Nullifying Infringement Claim CHESTER, NY /
RMS Medical Products Victory as U.S. Federal Circuit Court of Appeals Invalidates EMED Technologies Corp.'s Patent, Nullifying Infringement Claim CHESTER, NY / April 9, 2018 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR; the "Company") is pleased to announce
Read more →KRMDRMS Medical Products Announces Results for Three, Ten and Twelve Months Ending
RMS Medical Products Announces Results for Three, Ten and Twelve Months Ending December 31, 2017 - Highest reported twelve month net sales and net income in RMS history - Double digit percentage growth in net sales - Increased profitability CHESTER, NY / February 13, 2018 / Rep
Read more →KRMDRMS Medical Products Announces New FDA Clearance, Warning Letter Closed, and Organizational Changes - Resolution of FDA Warning Letter - Thanks to Eric Bauer for his service as Chief Operating Officer - CEO search proces
RMS Medical Products Announces New FDA Clearance, Warning Letter Closed, and Organizational Changes - Resolution of FDA Warning Letter - Thanks to Eric Bauer for his service as Chief Operating Officer - CEO search process initiated CHESTER, NY / November 22, 2017 / Repro Med
Read more →KRMDRMS Medical Products Posts Strong Results for Four-Month Period Ending
RMS Medical Products Posts Strong Results for Four-Month Period Ending June 30, 2017 RMS Medical Products reports double digit percentage growth in net sales both domestically and internationally, along with reduced SG&A including professional fees for the four-month period endi
Read more →KRMDRMS Medical Products Posts Third Quarter 2017 Results - Ongoing growth in revenue both domestically and internationally - Successful European sales meetings highlight strong demand abroad - Continued progress with FDA CH
RMS Medical Products Posts Third Quarter 2017 Results - Ongoing growth in revenue both domestically and internationally - Successful European sales meetings highlight strong demand abroad - Continued progress with FDA CHESTER, NY / December 27, 2016 / Repro Med Systems, Inc. db
Read more →KRMDRMS Medical Products Posts Second Quarter 2017 Results - Continued growth in core business masked by one-off project in comparable quarter - Successful IgNS 2016 Conference highlighted new product, previewed web redesign
RMS Medical Products Posts Second Quarter 2017 Results - Continued growth in core business masked by one-off project in comparable quarter - Successful IgNS 2016 Conference highlighted new product, previewed web redesign - Lean initiatives improving efficiency and manufacturing
Read more →KRMDRMS Medical Products Posts First Quarter 2017 Results - Double digit growth in revenue and adjusted EBITDA the result of accelerated sales and marketing efforts both domestically and international - Hosting first Interna
RMS Medical Products Posts First Quarter 2017 Results - Double digit growth in revenue and adjusted EBITDA the result of accelerated sales and marketing efforts both domestically and international - Hosting first International Distributor Meeting in Europe - Continued gross marg
Read more →KRMDRepro Med Systems, Inc. Posts Fourth Quarter and Fiscal Year 2016 Results and Announces New Member of the Board of Directors --Net revenues increased 9% year-over-year CHESTER, NY /
Repro Med Systems, Inc. Posts Fourth Quarter and Fiscal Year 2016 Results and Announces New Member of the Board of Directors --Net revenues increased 9% year-over-year CHESTER, NY / May 18, 2016 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced it
Read more →KRMDRepro Med Systems, Inc. Gives Business Update Including Preliminary Revenue Results for Q4 2016 CHESTER, NY /
Repro Med Systems, Inc. Gives Business Update Including Preliminary Revenue Results for Q4 2016 CHESTER, NY / March 31, 2016 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) announced that fourth quarter preliminary net revenues will exceed $3.2 million, represen
Read more →KRMDRepro Med Systems, Inc. Posts Strong Revenue Growth, Productivity Gains and Announces New Interim Chief Operating Officer CHESTER, NY /
Repro Med Systems, Inc. Posts Strong Revenue Growth, Productivity Gains and Announces New Interim Chief Operating Officer CHESTER, NY / December 23, 2015 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) announced that its net revenues for the third quarter ended
Read more →KRMDRepro Med Systems, Inc. (Repr) Announces Strong Results for Third Quarter Ended
Repro Med Systems, Inc. (Repr) Announces Strong Results for Third Quarter Ended November 30, 2014 CHESTER, NY / ACCESSWIRE / December 23, 2014 / Repro Med Systems, Inc. dba RMS Medical Products (OTC stock symbol REPR) today announced that its year-to-date net revenues for fiscal
Read more →KRMDRMS Medical Products Secures Additional Growth Capital Chester, NY / ACCESSWIRE /
RMS Medical Products Secures Additional Growth Capital Chester, NY / ACCESSWIRE / August 11, 2014 / Repro-Med Systems Inc., d/b/a RMS Medical Products (OTC stock symbol REPR) announced today that it secured growth capital commitments from the Horton Capital Partners Fund ("Horto
Read more →KRMDFor further information contact: Andrew I. Sealfon, President and CEO (845) 469-2042 RMS ANNOUNCES INCREASED SALES; ORGANIZATION AND PERSONNEL CHANGES (Chester, NY
For further information contact: Andrew I. Sealfon, President and CEO RMS ANNOUNCES INCREASED SALES; ORGANIZATION AND PERSONNEL CHANGES (Chester, NY - June 12, 2014) - Repro-Med Systems Inc., d/b/a RMS Medical Products (OTC stock symbol REPR) today announced a 41.1% increase i
Read more →KRMDREPRO-MED ANNOUNCES BOARD CHANGES, STOCK BUY-BACK PLAN (Chester, NY
REPRO-MED ANNOUNCES BOARD CHANGES, (Chester, NY - December 4, 2013) --- Repro-Med Systems, Inc., ( OTCBB: REPR ) d/b/a RMS Medical Products, has announced the resignation from its Board of Directors of Remo (Raymond) Spagnoli. Mr. Spagnoli had served as a director of the Company
Read more →KRMDREPRO-MED SYSTEMS, INC., REPORTS 29.9% INCREASE IN SALES FOR FISCAL YEAR ENDED FEBRUARY 29, 2012 AND SUCCESSFUL INTRODUCTION OF THE RMS HIGH-FLO SUBCUTANOUES SAFETY NEEDLE SETS Chester, New York
REPRO-MED SYSTEMS, INC., REPORTS 29.9% INCREASE IN SALES FOR FISCAL YEAR ENDED FEBRUARY 29, 2012 AND SUCCESSFUL INTRODUCTION OF THE RMS HIGH-FLO SUBCUTANOUES SAFETY NEEDLE SETS Chester, New York - June 7, 2012 - (PR NEWSWIRE) -- Repro-Med Systems Inc., (REPR.PK) d/b/a RMS Medica
Read more →KRMDFor further information: Andrew I. Sealfon, President RMS Medical Products 24 Carpenter Road, Chester, NY 10918 Telephone: (845) 469-2042 FAX: (845) 469-5518 FDA APPROVES MARKE
PRESS RELEASE DATED 05-31-2011 --------------------- For further information: Andrew I. Sealfon, President RMS Medical Products 24 Carpenter Road, Chester, NY 10918 Telephone: (845) 469-2042 FDA APPROVES MARKETING OF RMS SUBCUTANEOUS NEEDLE SETS (Chester, NY - May 31, 201
Read more →KRMDREPRO-MED SYSTEMS, INC., REPORTS 30% INCREASE IN REVENUE FOR FISCAL YEAR ENDED FEBRUARY 28, 2011 Chester, New York
PRESS RELEASE DATED 03-31-2011 REPRO-MED SYSTEMS, INC., REPORTS 30% INCREASE IN REVENUE FOR FISCAL YEAR ENDED Chester, New York - March 31, 2011 - (PR NEWSWIRE) -- Repro-Med Systems Inc, (REPR) dba RMS Medical Products, today announced unaudited financial results for its fisc
Read more →KRMDMEDICARE CLARIFICATION REIMBURSING THE FREEDOM60
PRESS RELEASE DATED SEPTEMBER 4, 2007 MEDICARE CLARIFICATION REIMBURSING THE FREEDOM60 WITH SUBCUTANEOUS IMMUNE GLOBULIN CHESTER, N.Y., September 4, 2007 -- According to a guidance document from Medicare's Region B contracting agent, the Freedom60, manufactured by Repro-Med
Read more →Competitive Position
How KRMD ranks across every disease it competes inCompetitive Position is a premium feature
See how KRMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial